Significant improvement seen in progression-free survival, but not overall survival, with addition of orteronel to androgen deprivation therapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, May 5, 2022 (HealthDay News) — For patients with newly diagnosed metastatic hormone-sensitive prostate cancer, the addition of orteronel to androgen deprivation therapy (ADT) significantly improves progression-free survival but not overall survival (OS), according to a study published online April 21 in the Journal of Clinical Oncology<\/em>.<\/p>\n Neeraj Agarwal, M.D., from the University of Utah Huntsman Cancer Institute in Salt Lake City, and colleagues randomly assigned patients with metastatic hormone-sensitive prostate cancer to ADT with orteronel or ADT with bicalutamide (638 and 641 patients, respectively). OS was compared as the primary objective, targeting a 33 percent improvement in median survival.<\/p>\n The researchers observed a significant improvement in progression-free survival (median, 47.6 versus 23.0 months; hazard ratio, 0.58; 95 percent confidence interval, 0.51 to 0.67) after a median follow-up of 4.9 years and in prostate-specific antigen level at seven months, but not in OS (81.1 versus 70.2 months; hazard ratio, 0.86; 95 percent confidence interval, 0.72 to 1.02). In the experimental versus control arm, there were more grade 3\/4 adverse events. Postprotocol life-prolonging therapy was received by 77.4 and 61.3 percent of patients in the control and experimental arms, respectively.<\/p>\n “Although the approximately 11-month improvement in median OS with orteronel appears clinically meaningful, it did not reach the prespecified requirement for statistical significance,” the authors write.<\/p>\n The study was partially funded by Millennium Pharmaceuticals Inc. (Takeda Pharmaceutical Company LTD), the manufacturer of orteronel.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n